Refine
Year of publication
Document Type
- Article (144)
- Preprint (37)
- Part of a Book (1)
Has Fulltext
- yes (182)
Is part of the Bibliography
- no (182)
Keywords
- BESIII (13)
- Branching fraction (8)
- e +-e − Experiments (8)
- Hadronic decays (5)
- Branching fractions (4)
- Lepton colliders (4)
- Quarkonium (4)
- Charmed mesons (3)
- Electroweak interaction (3)
- Exotics (3)
- Initial state radiation (3)
- Particle and Resonance Production (3)
- e+-e− Experiments (3)
- Bhabha (2)
- Biosynthetic mesh (2)
- Charm Physics (2)
- Charm physics (2)
- Charmonium (2)
- Cross section (2)
- Electroweak Interaction (2)
- Hadronic cross section (2)
- Incisional hernia (2)
- Leptonic, semileptonic & radiative decays (2)
- Muon anomaly (2)
- Particle decays (2)
- Pion form factor (2)
- QCD (2)
- Spectroscopy (2)
- Angular distribution (1)
- Annihilation (1)
- Antimuscarinic and Papaverine-Like Activity (1)
- BESIII detector (1)
- Born cross section measurement (1)
- CP violation (1)
- Charmonium (-like) (1)
- Complex hernia (1)
- Complications (1)
- Covariance matrix (1)
- Cross section measurements (1)
- Crystal and Molecular Structure (1)
- D meson (1)
- D0 and D+ mesons (1)
- Dalitz decay (1)
- Dark photon (1)
- Dark sector (1)
- D⁰ meson (1)
- Electromagnetic form factor (1)
- Electromagnetic form factors (1)
- Experimental nuclear physics (1)
- Experimental particle physics (1)
- FOS: Physical sciences (1)
- Flavor changing neutral currents (1)
- Flavor symmetries (1)
- Flavour Physics (1)
- Form factors (1)
- Hadrons (1)
- Hernia recurrence (1)
- Hernia surgery (1)
- High Energy Physics - Experiment (hep-ex) (1)
- Hyperons (1)
- Invisible decays (1)
- Mesh repair (1)
- Midline laparotomy (1)
- Neutrinos (1)
- Particle and resonance production (1)
- Particle phenomena (1)
- Polarization (1)
- Proton (1)
- Quantum chromodynamics (1)
- R value (1)
- Rare decays (1)
- Semi-leptonic decays (1)
- Sila-Substitution (1)
- Surgical site occurrence (1)
- Techniques Electromagnetic calorimeters (1)
- Triple quarkonia (1)
- Y (4260) (1)
- Y states (1)
- center-of-mass energy (1)
- charmonium-like states (1)
- dimuon (1)
- diphoton (1)
- e+e − annihilation (1)
- e+e⁻ − Experiments (1)
- e+e− annihilation (1)
- electron-positron collision (1)
- hadron spectroscopy (1)
- hadronic events (1)
- helicity amplitude analysis (1)
- inclusive J/ψ decays (1)
- luminosity (1)
- number of J/ψ events (1)
- tetraquark (1)
- trigger efficiency (1)
- Λ+c baryon (1)
- Σ hyperon (1)
Institute
- Physik (175)
- Medizin (4)
- Biochemie, Chemie und Pharmazie (1)
- Psychologie (1)
Background: Incisional heia is a frequent complication of midline laparotomy. The use of mesh in hernia repair has been reported to lead to fewer recurrences compared to primary repair. However, in Ventral Hernia Working Group (VHWG) Grade 3 hernia patients, whose hernia is potentially contaminated, synthetic mesh is prone to infection. There is a strong preference for resorbable biological mesh in contaminated fields, since it is more able to resist infection, and because it is fully resorbed, the chance of a foreign body reaction is reduced. However, when not crosslinked, biological resorbable mesh products tend to degrade too quickly to facilitate native cellular ingrowth. Phasix™ Mesh is a biosynthetic mesh with both the biocompatibility and resorbability of a biological mesh and the mechanical strength of a synthetic mesh. This multi-center single-arm study aims to collect data on safety and performance of Phasix™ Mesh in Grade 3 hernia patients.
Methods: A total of 85 VHWG Grade 3 hernia patients will be treated with Phasix™ Mesh in 15 sites across Europe. The primary outcome is Surgical Site Occurrence (SSO) including hematoma, seroma, infection, dehiscence and fistula formation (requiring intervention) through 3 months. Secondary outcomes include recurrence, infection and quality of life related outcomes after 24 months. Follow-up visits will be at drain removal (if drains were not placed, then on discharge or staple removal instead) and in the 1st, 3rd, 6th, 12th, 18th and 24th month after surgery.
Conclusion: Based on evidence from this clinical study Depending on the results this clinical study will yield, Phasix™ Mesh may become a preferred treatment option in VHWG Grade 3 patients.
Trial registration: The trial was registered on March 25, 2016 on clinicaltrials.gov: NCT02720042.
Introduction: Information on the long-term performance of biosynthetic meshes is scarce. This study analyses the performance of biosynthetic mesh (Phasix™) over 24 months.
Methods: A prospective, international European multi-center trial is described. Adult patients with a Ventral Hernia Working Group (VHWG) grade 3 incisional hernia larger than 10 cm2, scheduled for elective repair, were included. Biosynthetic mesh was placed in sublay position. Short-term outcomes included 3-month surgical site occurrences (SSO), and long-term outcomes comprised hernia recurrence, reoperation, and quality of life assessments until 24 months.
Results: Eighty-four patients were treated with biosynthetic mesh. Twenty-two patients (26.2%) developed 34 SSOs, of which 32 occurred within 3 months (primary endpoint). Eight patients (11.0%) developed a hernia recurrence. In 13 patients (15.5%), 14 reoperations took place, of which 6 were performed for hernia recurrence (42.9%), 3 for mesh infection (21.4%), and in 7 of which the mesh was explanted (50%). Compared to baseline, quality of life outcomes showed no significant difference after 24 months. Despite theoretical resorption, 10.7% of patients reported presence of mesh sensation in daily life 24 months after surgery.
Conclusion: After 2 years of follow-up, hernia repair with biosynthetic mesh shows manageable SSO rates and favorable recurrence rates in VHWG grade 3 patients. No statistically significant improvement in quality of life or reduction of pain was observed. Few patients report lasting presence of mesh sensation. Results of biosynthetic mesh after longer periods of follow-up on recurrences and remodeling will provide further valuable information to make clear recommendations.
Trial registration: Registered on clinicaltrials.gov (NCT02720042), March 25, 2016.